IP Library Granted Patent US 8,481,077
Granted Patent B2
US 8,481,077 · App. 13/402,409 · Granted Jul 9, 2013

Microbubbles and methods for oxygen delivery

Inventors: John Kheir (Brighton, MA); Mark Andrew Borden (New York, NY); Francis X. McGowan (Wellesley Hills, MA)
Assignees: The Trustees of Columbia University in the City of New York; Children's Medical Center Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,481,077
App. No.
13/402,409
Granted
Jul 9, 2013
Kind
B2
Abstract

Compositions containing a carrier and microbubbles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen/dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs.

Claims (22)

1. A method for delivering oxygen to a patient, comprising

administering via injection or infusion to the patient a composition, comprising a suspension comprising microbubbles and a carrier, wherein the microbubbles comprise a lipid envelope and a gas core, wherein the gas core comprises oxygen and does not contain a fluorinated gas, wherein the lipid envelope comprises one or more lipids, wherein the lipid is a phospholipid comprising acyl chains having an average length of 10 to 24 carbons, wherein the outer surface of the lipid envelope forms a protective border, and wherein the suspension comprises at least 40% oxygen by volume,

wherein the patient is experiencing local or systemic hypoxia,

wherein the composition is administered in an effective amount to increase the concentration of oxygen in the patient's blood, tissue or organ in need of oxygen, and

wherein the microbubbles release the effective amount of oxygen within 0.5 seconds to 1 minute following administration to the patient.

2. The method of claim 1 , wherein the lipid envelope is a monolayer.

3. The method of claim 1 , wherein the oxygen is administered via injection.

4. The method of claim 1 , wherein the hypoxic conditions arise in the patient as a result of a disease or disorder selected from the group consisting of congenital physical or physiologic diseases or disorders, embolisms, peripheral artery occlusive disease, transient ischemic attacks, strokes, acute trauma, surgical interventions, and exposure to chemical or environmental agents.

5. The method of claim 1 , wherein the suspension comprises 40 to 70% oxygen by volume.

6. The methods of claim 1 , wherein the composition is administered at a rate of 0.5 to 400 mL/minute.

7. A method for delivering oxygen to a patient, comprising

administering via injection or infusion to the patient a composition, comprising a suspension comprising microbubbles and a carrier, wherein the microbubbles comprise a lipid envelope and a gas core, wherein the gas core comprises oxygen and does not contain a fluorinated gas, wherein the lipid envelope comprises one or more lipids, wherein the lipid is a saturated diacyl phosphatidylcholine having the formula Di-C n -PC, where n is between 12 and 24, wherein the outer surface of the lipid envelope forms a protective border, and wherein the suspension comprises at least 40% oxygen by volume,

wherein the patient is experiencing local or systemic hypoxia,

wherein the composition is administered in an effective amount to increase the concentration of oxygen in the patient's blood, tissue or organ in need of oxygen, and

wherein the microbubbles release the effective amount of oxygen within 0.5 seconds to 1 minute following administration to the patient.

8. The method of claim 7 , wherein the lipid is a saturated diacyl phosphatidylcholine having the formula Di-C n -PC, where n is 16 or 18.

9. The method of claim 1 , wherein the microbubbles are stable at 4° C. and standard pressures for weeks to months.

10. The method of claim 7 , wherein the lipid envelope further comprises a sterol.

11. The method of claim 1 , wherein the amount of oxygen that is released is effective to raise the oxygen content of circulating blood.

12. The method of claim 11 , wherein the amount of oxygen that is released is effective to restore PO 2 levels to normal levels.

13. The method of claim 11 , wherein the amount of oxygen that is released is effective to resuscitate the patient's heart.

14. The method of claim 1 , wherein the oxygen is administered as a continuous infusion.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 22, 2022
From: BOSTON'S CHILDREN HOSPITAL
To: UNITED STATES GOVERNMENT
Reel/Frame 059862/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: KHEIR, JOHN; MCGOWAN, FRANCIS X.
To: THE CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 027749/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: BORDEN, MARK ANDREW
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 027749/0735 →
Continuity (5)
Division 12240704 · Sep 29, 2008
Provisional Application 61073334 · Jun 17, 2008
Provisional Application 61026984 · Feb 7, 2008
Provisional Application 60975705 · Sep 27, 2007
Related Publication 20120156300A1 · Jun 21, 2012